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Summary Treatment of knee cartilage defect, a true challenge, should not only reconstruct
hyaline cartilage on a long-term basis, but also be able to prevent osteoarthritis. Osteochon-
dral knee lesions occur in either traumatic lesions or in osteochondritis dissecans (OCD). These
lesions can involve all the articular surfaces of the knee in its three compartments. In princi-
ple, this review article covers symptomatic ICRS grade C or D lesions, depth III and IV, excluding
management of superﬁcial lesions, asymptomatic lesions that are often discovered unexpect-
edly, and kissing lesions, which arise prior to or during osteoarthritis. For clarity sake, the
international classiﬁcations used are reviewed, for both functional assessment (ICRS and func-
tional IKDC for osteochondral fractures, Hughston for osteochondritis) and morphological lesion
evaluations (the ICRS macroscopic evaluation for fractures, the Bedouelle or SOFCOT for osteo-
chondritis, and MOCART for MRI). The therapeutic armamentarium to treat these lesions is
vast, but accessibility varies greatly depending on the country and the legislation in effect.
Many comparative studies have been conducted, but they are rarely of high scientiﬁc quality;
the center effect is nearly constant because patients are often referred to certain centers for
an expert opinion. The indications deﬁned herein use algorithms that take into account the size
of the cartilage defect and the patient’s functional needs for cases of fracture and the vitality,
stability, and size of the fragment for cases of osteochondritis dissecans. Fractures measur-
ing less than 2 cm2 are treated with either microfracturing or mosaic osteochondral grafting,
between 2 and 4 cm2 with microfractures covered with a membrane or a culture of second-
or third-generation chondrocytes, and beyond this size, giant lesions are subject to an excep-
tional allografting procedure, harvesting from the posterior condyle, or chondrocyte culture on
a 3D matrix to restore volume. Cases of stable osteochondritis dissecans with closed articular
cartilage can be simply monitored or treated with perforation in cases of questionable vitality.
Cases of open joint cartilage are treated with a PLUS ﬁxation if their vitality is preserved; if
not, they are treated comparabl
on the defect size.
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Table 1 Hughston Score.
Excellent 4 Normal sports activity
No functional symptom
Normal clinical examination
Good 3 Normal sports activity
Pain on intense activity
Normal clinical examination
Fair 2 Pain and hydrarthrosis if intense
activity
Sport normal
Normal clinical examination
Poor 1 Pain and hydrarthrosis if moderate
activity
Loss of ﬂexion less than 20◦
Failure 0 Cessation of sports activity
Pain and hydrarthrosis in daily
activities
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Introduction
Cartilage tissue has mechanical properties that allow move-
ment of the joint surfaces, by combining absorption of
stresses, low friction, and high resistance to wear. Despite
its mechanical performance, cartilage tissue lacks blood and
nerve vessels: the cells are supplied by diffusion through
the extracellular matrix. This all suggests that in a complex
mechanical context, the low metabolic activity of cartilage
tissue protects it from excessive physical stresses. How-
ever, vascular paucity results in cartilaginous lesions having
a low spontaneous repair potential. Development of surgi-
cal techniques is in full expansion with the major challenge
of hyaline cartilage reconstruction on a bone base, the only
long-lasting and viable solution for cartilage lesions. This is
the therapeutic challenge for the coming decades.
Lesion assessment
Three factors are used to assess the initial cartilage lesion:
the patient’s clinical status and the lesion’s size and type.
The indication for management is based on the deteriora-
tion of the functional status measured by pain and functional
limitation; these criteria are validated by a number of clin-
ical scores [1]. The most frequently used functional scores
are the International Cartilage Repair Society (ICRS) score,
the International Knee Documentation Committee (IKDC)
functional score, and the Hughston score. The ICRS is a
validated score used to evaluate the repair of cartilage
lesions, to evaluate the functional status (normal, nearly
normal, abnormal, and severely abnormal), to compare the
injured side with the healthy side (as a percentage of the
healthy side), to evaluate pain using an analogic pain scale,
and to classify the sports level from normal to severely
abnormal [2]. The functional IKDC has not been speciﬁ-
cally validated for cartilage lesions, but it is a frequently
used score. It evaluates, from 0 to 100, the level of activ-
ity with no pain, stiffness, effusion, locking, the patient’s
sports activities, and the knee’s optimal functioning. The
functional IKDC is completed by the physical IKDC, which
assesses intra-articular effusion, loss of range of motion,
ligament laxity, joint cracking (crepitus), disease related
to grafting sites, and hopping on one foot. It is also used
to analyze radiographic images. Each group of clinical and
radiographic criteria is classiﬁed in grades: normal, nearly
normal, abnormal, and severely abnormal. A ﬁnal grade is
given to the patient corresponding to the lowest grade [3,4].
The Hughston score is more speciﬁcally used by pediatric
orthopaedic physicians and was designed to assess the treat-
ment of osteochondritis lesions in children [5,6]. It classiﬁes
patients into ﬁve clinical categories from failure to an excel-
lent clinical result (Table 1).
The lesion size can be measured in different ways. The
standard radiological work-up can be used to estimate the
width on the AP view of the knee and the length on the
lateral knee image. However, the CT arthrogram, MRI, and
arthro-MRI provide a more precise appreciation of the width
on AP slices and length on sagittal slices; this measurement
makes it possible to calculate the surfaces. Arthroscopy
directly measures the size of the lesion using either a probe,
cylindrical gauges, or the measurement of the lesional
•Loss of ﬂexion greater than 20◦
rc described by Robert. Directly visualizing the lesion,
rthroscopy can appreciate the depth of the lesion using
he ICRS grades:
grade 1: nearly normal (superﬁcial lesions): softening, ﬁb-
rillations, lacerations, ﬁssures;
grade 2: abnormal (less than 50% of cartilage depth);
grade 3: severely abnormal (cartilage defects extending
down to more than 50% of cartilage depth);
grade 4: severely abnormal (lesion extending past sub-
chondral plate, bone exposed).
According to the ICRS guidelines, the seat of the lesion
s represented by identifying the location of the cartilage
nvolvement on drawings of the articular surfaces: a lateral
iew of the knee, an AP view in perspective of the femur, a
uperior view of the tibia in perspective, and an inferior view
f the patella in perspective. There are four speciﬁc radio-
raphic classiﬁcations for osteochondritis lesions in children
OCD). Two locate the lesions on the AP and lateral images
f the knee: the Cahill and Berg [7], (Fig. 1) and Harding [8],
Fig. 2) classiﬁcations. The two other classiﬁcations evalu-
te the radiological signs of OCD, classifying lesions into four
athological stages: the Bedouelle [9] and Hughston et al.
lassiﬁcations [6].
Bedouelle classiﬁcation:
stage 1: clearly incomplete well-deﬁned image (Ia) with
more or fewer calciﬁcations within (Ib);
stage 2: presence of a nodule (IIa) with more or less shrink-
age of the nodule in relation to the condyle (IIb);
stage 3: sleigh-bell aspect;
stage 4: free fragment in the joint with an empty with an
empty bed.
Hughston et al. classiﬁcation:stage 0: osteoarthritis, or impingement of the joint space
greater than 50%;
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Figure 1 Diagram: Cahill and Berg classiﬁcation. Zone 1:
medial condyle (internal half). Zone 2: medial condyle (external
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Figure 2 Diagram: Harding classiﬁcation. Zone A: in front of
the Blumensaat line. Zone B: between zone A and C. Zone C:
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talf). Zone 3: femoral notch. Zone 4: lateral condyle (internal
alf). Zone 5: lateral condyle (external half).
stage 1: condyle irregularities, impingement of the joint
space less than 50%;
stage 2: condyle ﬂattening;
stage 3: healing zone with defect or sclerosis;
stage 4: normal radiographic image.
The ICRS recommends MRI for the diagnosis and evalua-
ion of cartilage lesion repairs, a noninvasive, reproducible
xam that, when done well, is precise and informative. In
he literature, there is consensus on advising two sequences
hat are simple to perform: the fast spin-echo (FSE) T2-
eighted sequence, which shows effusion, bone edema, and
lteration of the cartilage surface, and the 3D GRE T1-
eighted sequence, which reveals alterations in cartilage
hickness and provides very precise information on the sub-
hondral bone. These two sequences are used to determine
he lesion’s ICRS grade. To evaluate cartilage repair, the
OCART score [10,11] is used, which is based on nine cri-
eria: ﬁlling at the edges (lateral integration), condition of
he surface (lamina splendens), homogeneity of the struc-
ure, type of signal on the FSE T2-weigted sequence, type
f signal on the 3D GRE FS sequence, presence of a subchon-
ral radiolucent line, examination of the subchondral bone,
resence of adherences and visualization of effusion.
urrent therapeutic methods
he therapeutic tools aim to ﬁll the cartilage loss so as
o restore joint congruence, if possible to induce hya-
ine healing and thus prevent long-term osteoarthritic
egeneration. They can be classiﬁed into subchondral stim-
lation repair methods, most frequently resulting in a
m
p
b
tehind the tangential line to the posterior cortex of the femoral
iaphysis.
brous scar (microfracturing, Pridie drilling, and abrasion),
econstruction methods contributing mature cartilage to
he osteochondral unit (mosaicplasty and osteochondral
llografting for massive chondral defects), and regenera-
ion through grafting autologous chondrocyte cells aiming
or hyaline repair. Nevertheless, the follow-up biopsies
re often disappointing, with hyaline cartilage frequently
bsent even in very costly regeneration using cell culture
mplantation techniques.
icrofracturing
icrofracturing is a reference repair technique to which the
nternational literature compares all emerging techniques.
nitially described by Richard Steadman et al. [12] and ﬁrst
eported in 1997 [13], microfracturing should not be con-
used with Pridie drilling with a motorized drill and bit,
ven if this technique is widely used in France with identical
istological and tissue objectives.
The principle of this technique is to obtain healing of the
artilage defect with mesenchymal stem cells contained in
ubchondral bone that will colonize a ﬁbrous clot favoring
reation of substitution cartilage. The technique initially
escribed by Steadman et al. [13] consisted in débride-
ent of the lesion’s edges, delicate ablation of the calciﬁed
laque, or ‘‘tidemark,’’ and then drilling microfractures to
he vascularized subchondral area. These microfractures are
ade with a thin square nail or, better yet, with angulated
unches every 3—4mm and 3—4mm deep. Bleeding should
e present, clearly visible without or upon removing the
ourniquet (Fig. 3). This bleeding will induce the creation of
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res with bleeding control.
chondrogenesis) technique consisting of covering a
microfracture with a collagen (I/III) membrane: the
Chondro-Gide® (Fig. 4A, B). The matrix can be glued in the
cartilage loss area with biological glue, with the porous side
of the matrix remaining in contact with the bone surface
or sutured with resorbable sutures like ﬁrst-generation
chondrocyte cultures. As shown by Dickhut et al., the
matrix allows chondrogenic differentiation of human stem
cells in vitro [22] but also the deposit of proteoglycans.
This technique has a number of advantages: a procedure
performed in a single intervention, low risk of hemarthrosis,
protection and stabilization of the ﬁbrous clot, absence of a
donor site, and a moderate price (the price of the matrix),
with no costly cell culture. Deep osteochondritis-type
lesions are treated with a complement to AMIC based on
a grafting technique of cancellous bone enriched with
platelet-rich plasma [23]. Gille et al. [24] and Pascarella
et al. [25] have reported the results of their experience,
showing signiﬁcant improvement in function in level 4
studies. In a series of 19 cases with a mean follow-up of
24months, Pascarella et al. obtained 78% satisﬁed patients
with an IKDC score improving from 30 to 83. Gille and
Behrens reported a series of 32 lesions in 26 patients with
a mean 36months of follow-up: 87% of the patients seen
again were satisﬁed, but the ICRS decreased with time,
going from 31 to 59 at 12months, 68 at 24months, 54
at 36months, and 37 at 48months, a regression similar
to simple microfracturing, even though this decrease in
the score was not statistically signiﬁcant. Benthien and
Behrens [26] reported on its advantages in the treatment of
patellar lesions. A recently reported small series studied byFigure 3 Microfractu
a superclot, colonized by multipotent stem cells, platelets,
and growth factors. After multiplication and dedifferenti-
ation of the mesenchymal cells in this clot, a substitution
ﬁlling tissue appears, which is for the most part ﬁbrocar-
tilaginous with type I collagen. Naturally, the properties of
the ﬁbrocartilage are different, inevitably leading to dete-
rioration and raising the question of maintaining the results
over the long term.
Even though the microfracturing technique has never
been assessed in France, a survey on practices con-
ducted by the French Arthroscopy Society (Société Franc¸aise
d’Arthroscopie) showed that microfracturing is only used
by one-third of the surgeons who treat cartilage lesions,
the majority preferring mosaicplasty and the Pridie drilling
technique.
In the literature, four level 1 studies [14—17] showed
that the results of microfracturing are quite good, compa-
rable to chondrocyte culture grafting, less effective than
mosaicplasty. However, the follow-up period in these stud-
ies was short. A recent powerful meta-analysis carried out
by Mithoeﬂer et al. [18] combined 28 studies with a total of
3122 patients with a mean follow-up of 41months. It con-
cluded that microfracturing gives good early results for good
ﬁlling of cartilage defects but with ﬁbrous tissue, explaining
the secondary deterioration beginning at 2 years of follow-
up. This regression is even more frequent in that the study
reporting these microfracturing results has a high level of
evidence and that the patients studied were very active.
This technique seems to have a negative inﬂuence on sec-
ondary chondrocyte culture for cases of failure, contrary to
generally accepted notions.
In conclusion, this technique currently used in all of the
randomized comparative studies, except in France, is sim-
ple, can be done with arthroscopy throughout the knee, is
economical, and provides good initial results. Since it pro-
duces ﬁbrocartilage, the results deteriorate over time. It
is particularly indicated for patients with a low functional
demand and for lesions discovered accidentally that mea-
sure less than 4 cm2.
PLUS microfracturing
This is a more recent technique whose principle is
microfracturing covered by a protective membrane (perios-
teum or synthetic matrix). Based on the research of Breinan
et al. [19,20], Behrens et al. [21], and Jakob since 2003
have developed the AMIC (autologous matrix-induced
Figure 4 A. PLUS microfractures before placing the mem-
brane. B. PLUS microfractures with membrane in place.
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erdonk’s team [27] challenges the value of this technique
ecause of the absence of signs of repair on MRI and
articularly the early appearance of osteophytes in three
ases out of ﬁve, despite early favorable clinical results.
D acellular scaffolds
hree-dimensional scaffolding is an acellular ﬁlling sub-
titute made up of multilayered biomimetics (Fig. 5;
aioRegen®) alternating layers of type I collagen and layers
f collagen and calcium hydroxyapatite in variable propor-
ions. This technique, used notably at the Rizzoli Institute
28], has the major advantages of ﬁlling osteochondral loss
ith matrix while forgoing autologous chondrocyte culture,
ll within a single operation. Different cellular recruitment
xists at each layer of this matrix placed on a freshened
nd bleeding background. The preliminary results of this
ew and simple method [28] are encouraging at the very
hort follow-up time of 6months, showing stability and
hen resorption of the implant and complete ﬁlling of the
efect both macroscopically and with MRI, as well as func-
ional improvement. Histologically, no ossiﬁcation has been
bserved; however, a mixed tissue is maturing. Clinical,
orphological, and histological assessment is therefore nec-
ssary over a longer time span.
osaicplasty
his technique was created and then developed further by
aszlo Hangody based on an animal study on the horse begun
n 1992. This widespread technique, the reference in France,
as been the subject of two multicenter studies among the
FA members detailing the indications and the results at the
edium term.
This demanding technique consists in a transfer of an
natomic and functional osteochondral unit harvested on
he knee presenting an osteochondral lesion in a single
pen operation or under arthroscopy (Fig. 6A and B). The
raft made is comparable on the macroscopic level to laying
obblestones, allowing the surgeon to obtain bone integra-
ion, the presence of hyaline cartilage on the pegs, but a
brous cartilage interface. Over the short term, the mosaic
raft is a validated cartilage restoration technique [29]. Dif-
erent studies have taken an interest in the harvest site.
n 2005, Garretson et al. demonstrated that the optimal
nd less restrictive site was the edges of the superomedial
rochlea. As for the size and number of pegs, in a teaching
t
l
l
h
Figure 5 Maioregen® 3igure 6 A. Open mosaicplasty. B. Arthroscopic mosaicplasty.
ession Robert [30] detailed the respective advantages of
mall and large pegs. The large pegs provide greater sta-
ility, less substantial ﬁbrous interpositions, and a greater
artilage surface, at the cost of more difﬁcult ﬁlling in
ases needing multiple pegs and of probable greater mor-
idity with harvesting. Sgaglione [31] recommends 6- to
-mm-wide pegs between 15 and 20mm long. With time, a
endency to use increasingly large pegs has been observed.
his harvesting comes with a certain morbidity, estimated
t 0—36% in the literature [32,33]. Following harvesting on
healthy knee for talar lesions, Reddy et al. [32] reported
our painful knees out of 11 at 4 years of follow-up. On the
ther hand, Iwasaki et al. [33,34] reported no complications
f harvesting for humeral lesions at 2 years of follow-up.
n a heterogeneous retrospective study on more than 1000
osaic grafts, Hangody et al. [35] reported 3% morbidity
ith four infections and 36 cases of hemarthrosis. They also
valuated the role played by the location of the lesion,
nding a positive inﬂuence of medial condylar lesions with
2% good and very good results compared to 87% for lateral
ondylar lesions and 79% for patellofemoral lesions.
The utility of MRI assessment is recognized by all, par-
icularly when using ICRS sequences and the MOCART score.
t 9 years of follow-up, Tetta et al. [36] studied 24 patients
reated with mosaicplasty, with complete integration of the
raft in 75% of the cases, correlated with the MOCART score.
From the point of view of the overall result, the good
nd very good results reported in the literature range from
2 to 92% at more than 8 years of follow-up. The factors for
he best prognosis are usually found for lesions located on
he medial condyle, osteochondritis desiccans, deep, small
esions, and the shortest time to surgery possible. Large
esions have the least favorable prognosis. No correlation
as been found between the size of the harvested tissue
D multilayer matrix.
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and the development of patellofemoral osteoarthritis, often
at its beginnings and only radiologically visible: 13% at a
mean follow-up of 8 years for the SFA and 3% for Hang-
ody et al. [35]. Mosaic grafting therefore seems to be a
reliable technique at the short and long term. Much less
expensive than the regenerative techniques, performed in
a single surgical step, and providing immediate restoration
of the cartilaginous surface while treating the entire osteo-
chondral unit, mosaicplasty nevertheless remains a difﬁcult,
demanding technique not without complications. The limita-
tion of the technique matches the size of the lesion to treat.
The choice indication is a deep and small (less than 2 cm2)
lesion located on the medial condyle. Beyond 2 cm2, Imhoff’s
team [37,38] has used 20- or 35-mm-diameter autologous
grafting performed at the expense of the homolateral poste-
rior condyle using the Méga OATS® ancillary instrumentation
(Fig. 7). The largest series reported 33 cases operated for
condylar lesions that were a mean 6.2 cm2 reviewed with a
mean follow-up of 66months. Thirty-one of the 33 patients
had signiﬁcantly improved and were willing to undergo the
operation again.
Osteochondral grafting for massive chondral
defectsThe ﬁrst use of osteochondral grafting for massive chon-
dral defects dates from Lexer’s work in 1908. The technique
consists in using a fresh or frozen epiphyseal osteochondral
allograft placed in an area of voluminous osteochondral loss
c
p
f
w
Figure 8 Condylar osteS145
repared by drilling. The graft can be positioned with press-
t technology or ﬁxed with buried screw ﬁxation (Fig. 8).
his technique is reserved for substantial cartilage loss,
sually more than 4 cm2, a truly salvage treatment. Sev-
ral series have reported satisfactory results in more than
5% of cases with a mean follow-up of 10 years [39—41].
hese results seem less good with longer follow-up peri-
ds, decreasing from 95% for 5 years of follow-up to 66%
t 20 years of follow-up [42,43]. Screw ﬁxation seems to
ive better results (94% good results), improving bone ﬁx-
tion [44]. Jamali et al. [45] reported less satisfactory
esults on the knee with the appearance of signs of early
atellofemoral osteoarthritis in half the cases. On the tibia,
series of post-traumatic lesions of the tibial plateau
eported favorable results in 67% over the long term, compa-
able to femoral allografts, with failures appearing during
rthroplasty. Preoperative joint impingement is a poor prog-
ostic factor, as is allografting on kissing lesions [40].
Nonetheless, since this technique has rarely been used,
o level 1 or 2 study can be found in the literature. Those
vailable are retrospective studies with expert opinion. This
echnique requires a certiﬁed tissue bank and the cost is
igh. Yet recuperation of posterior condyle in bone banks
ould facilitate the dissemination of this technique.
utologous chondrocyte culture grafting
irst-generation grafts
idely developed, used and disseminated by Lars Peter-
on and Matts Brittberg’s [46] Swedish school and then
y Tom Minas, the principle involves placing within the
rimmed and bloodless defect a culture of autologous chon-
rocytes that have undergone in vitro multiplication in the
aboratory, implanted under a patch of periosteum har-
ested locally from the tibia and sutured to the edges of
he cartilage loss before impermeabilization with biologi-
al glue (Fig. 9). Cell multiplication and maturation should
ccur and ﬁll the defect with hyaline cartilage. This is an
xpensive technique, whose results remain controversial, in
articular in comparative studies with mosaicplasty [47] and
ven microfracturing by Knutsen et al. [16]. Results have
een published by a number of authors, including Brittberg
nd Peterson, who published the long-term results of this
echnique [48,49]; the histological results were not always
onsistent [15,47]. The results are reported for the most
art on Swedish series in which the early follow-up includes
ew patients lost to follow-up. Biopsies were performed
ith conﬁrmation of the hyaline-like phenotype. Micheli
ochondral allograft.
S146 G. Versier, F. Dubrana
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in terms of osteoarthritis prevention remains uncertain. A
number of comparative studies of simple and inexpensive
repair techniques such as microfracturing [16] and mosaic-
plasty [15,54—56] have not demonstrated the superiority
of cellular cultures. Only Bentley et al. [56] found that
ﬁrst-generation chondrocyte grafting was better. This study
examined more voluminous lesions up to 12.2 cm2 and the
mosaic grafting technique used small-diameter samples.
Second-generation grafting
To prevent the problems related to the periosteum patch
(ossiﬁcation, detachment, calciﬁcations, leakage), matrices
have been developed serving as artiﬁcial membranes. These
matrices can be synthetic (carbone, polylactic or polygly-
colic acid, or dacrylen), proteic (collagen, ﬁbrin, gelatin), or
polysaccharid (alginate, agarose, hyaluronic acid). Particu-
larly advantageous, hyaluronic acid, an extracellular matrix
homeostasis drug, acts by its interaction with CD44 and I-
CAM 1. It also ﬁghts against chondrocyte apoptosis, oxidative
stress, inhibits the catabolic interleukin IL-1 according to
Fukuda, and produces metalloproteases according to Juvoli.
Its chondrogenic effect occurs in stimulating differentiation,
regulating the matrix structure during chondrogenesis, and
inﬂuencing cellular mobility, differentiation, and develop-
ment.
As early as 2002, Saris et al. [57] developed the culture
of chondrocytes selected for the presence of markers of
preservation of the phenotypic characteristics required
for differentiation and maturation to obtain hyalin car-
tilage [58], a culture that is injected on a membrane
(Chondroselect®) during surgery. This cell therapy can estab-
lish a ‘‘chondrogenic potential score’’ for the culture
implanted. In a highly rigorous level 1 study comparing 57
cases undergoing this technique (Fig. 10) with 61 patients
treated with microfracturing, Saris showed a signiﬁcant dif-
ference in favor of chondrocyte implantation at 3 years of
follow-up, both clinically using both the Knee injury andigure 9 Cell culture of chondrocytes with periosteal patch.
t al. [50] reported a series of 50 patients with a minimum
ollow-up of 36months, noting that a 5-point increase in the
odiﬁed Cincinnati score; 84% of the patients had increased
unction, 2% remained the same, and 13% declared that their
unction had deteriorated. Peterson et al. [51] published
heir results on 94 patients with follow-up between 2 and
years. The results varied depending on the location of the
efects: for the patella, the results were good in 62% of the
ases and increased to 85% if medialization of the anterior
ibial tuberosity was associated. For the condylar lesions,
2% good results have been announced. Condylar osteochon-
ritis seems a good indication since the results were good
n 16 out of 18 patients. Biopsies show hyaline-like tissue
ith type II collagen in immunohistochemistry. In 10—15% of
he cases, biopsies showed an exaggerated response. At the
edium term, Peterson et al. [51] reported a series of 61
atients with a mean follow-up of 7.4 years. The good results
ere stable over time: 81% at 2 years and 83% between 5 and
1 years of follow-up. The failure rate was 16% and appeared
n the ﬁrst 2 years. Cole and Lee [52] reported a series of
03 cases of cartilage loss in 83 patients evaluated with the
incinnati, IKDC, Tegner, Lysholm, and SF-12 scores. All the
cores improved signiﬁcantly in 30 patients with a minimum
ollow-up of 2 years; 79.3% of the patients declared they had
mproved.
Recently, Peterson et al. [53] reported the long-term
esults of the ﬁrst 341 cases in a level 4 study (retrospec-
ive study with one-third lost to follow-up), with a mean
ollow-up of 12.8 years and for lesions that measured a
ean 5.3 cm2 in size. Seventy-four percent of the patients
ontinued to improve beyond the 10th year and 92% were
atisﬁed and willing to undergo the same operation if nec-
ssary. Although the initial presence of a kissing lesion
orsened the long-term results, meniscectomy, age at the
ime of surgery, and the lesion size did not inﬂuence the
esults at the longest follow-up. From and medical-economic
erspective, autologous chondrocyte cultures are much
ostlier than prostheses, and for the moment the beneﬁt
Figure 10 Chondrocelect® technique (second-generation
ACI).
Treatment of knee cartilage defect in 2010 S147
Osteoarthritis Outcome Score (KOOS) and the MOCART score
on MRI, with 83% good results versus 62%. The best results
were observed for lesions treated early and when the culture
implanted had a better ‘‘chondrogenic potential score,’’
which argues in favor of continuing the research in this tech-
nique of improving cell therapy.
Third-generation chondrocyte grafting
These more recent techniques are still being evaluated.
Their principle is culturing chondrocytes in an implantable
biological matrix with ideal properties: biocompatible,
biodegradable, and bioactive while preserving the pheno-
typic characteristics, thus favoring the cellular proliferation
and synthesis of the extracellular matrix, which is perme-
able, easy to use, and inexpensive. Here again hyaluronic
acid is often used. Beginning in 2002, Marcacci et al. [59]
developed a chondrocyte culture termed ‘‘third genera-
tion,’’ on a matrix of esteriﬁed hyaluronic acid, Hyalograft
C®; this matrix can be superimposed in several layers
using a so-called mushroom technique (Fig. 11), thus ﬁlling
deep cartilage loss in several thicknesses. This technique
is also currently used by Brittberg. This procedure has
three phases: ﬁrst arthroscopic with débridement and
chondrocyte harvesting, second classical cell culturing for
approximately 3weeks in presence of the matrix to obtain
at least 4 million chondrocytes/cm2 in presence of growth
factors (TGF, BMP, IGF) and stabilizers; and third, surgery
(patella) or arthroscopy (tibia, femur) for débridement,
placing biological glue, and 3D cell implantation, possi-
bly stacking several layers. Preliminary results have been
reported by the precursors [60,61]. Clinical evaluation has
reported no level 1 or 2 studies to date, and one level 3 non-
randomized prospective study [28] with, at a mean 5 years
of follow-up, a signiﬁcant improvement in clinical scores,
with a functional IKDC score improving from 39 to 80, and
an MRI evaluation using the MOCART score showing inte-
gration of the graft in 60% of the cases. Nevertheless, the
series of patients was very inhomogeneous, with half of this
small series originating from relevant associated ligament
or meniscus repair. From a histological perspective, 55% of
the biopsies found hyaline cartilage, 18% mixed cartilage,
and 27% ﬁbrocartilage. These results seem to be improved
over time with 83% hyaline cartilage beyond 18months [62],
showing the need for a long-term study of this technique.
Figure 11 Brittberg mushroom technique.
In a level 2 study, Zeifang et al. [63] found no signiﬁcant
difference between ﬁrst-generation chondrocyte grafting
with a periosteum patch and third-generation chondrocyte
grafting in a matrix foundation, with certain clinical results
at 2 years of follow-up even favoring the oldest technique.
In three-dimensional regeneration methods, the
Cartipatch®, from the TBF laboratory developed and
assessed in France, seems to give results that are compara-
ble with an algarose and alginate matrix (Fig. 12) during a
phase II study (subjective IKDC score increasing from 36 to
85 at 18months of follow-up), which needs to be conﬁrmed
in an upcoming prospective, randomized multicenter phase
III study [64].
Surgical indications
The ideal patient who may have the best result is a patient
who is less than 50 years of age, for biological and cellular
reasons, but also because of lower eligibility in terms of indi-
cation for arthroplasty. The discomfort must be severe and
resistant to well-conducted medical treatment. The knee
must be stable, with a favorable axis, i.e., unloading the
Figure 12 Culture with Cartipatch® culture.
Figure 13 Aspect of a patellar cartilaginous lesion in T2 map-
ping.
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cigure 14 Mega-osteochondral graft sacriﬁcing the posterior
ondyle according to Imhoff.
esion, with no morbid obesity (BMI < 30). Smoking is unfa-
orable for bone healing and therefore unfavorable for deep
esions, but nothing in the literature proves that this holds
rue for cartilage, which is avascular. The lesion to treat
ust be deep (ICRS grade 3 or 4) on a single surface, and
issing lesions should not be treated surgically. The lesion’s
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ize must be large enough, greater than 0.5 cm2, without
t being possible to deﬁne a maximum size, with occasion-
lly indications for salvage surgery. We emphasize that in
ll cases this is not surgery for osteoarthritis. The absolute
ontraindications that have been recognized are obesity,
oint impingement, and inﬂammatory diseases; others are
elative because they can be dealt with at the same time,
articularly for procedures in a single operation (microfrac-
uring and mosaicplasty) or before cartilage treatment:
igament laxity stemming from ligament reconstruction, axis
efect to be treated with osteotomy and weight loss. Many
uthors advocate nearly systematic realignment osteotomy.
revious meniscectomy does not compromise the result.
owever, early treatment should be pursued. Beyond clini-
al evaluation, MRI is now the reference examination with
CRS sequences (2D or 3D FSE T2 FS and 3D GRE T1 FS),
hich allow calculation of the MOCART score. In the future,
2 mapping (Fig. 13), which analyzes the deterioration of
ollagen ﬁbers, will allow routine, more precise cartilage
ssessment. Arthroscopy can be part of the workup, notably
f chondrocyte grafting is planned.
The available armamentarium is rich, but is not accessi-
le to everyone, particularly in France where legislation is
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Figure 16 Arthroscopic screw ﬁxation in a case of osteochon-
dritis dissecans.
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ticularly if the pegs are supported by an interpeg graft:
between 2 and 4 cm2, third-generation chondrocyte grafting
is the best choice, and beyond this condylar mega-OATS® or
allografting.Treatment of knee cartilage defect in 2010
unfavorable to research. Palliative repair procedures using
subchondral stimulation produce ﬁlling with ﬁbrocartilage
and are easy to perform under arthroscopic guidance. Prac-
ticable in all the compartments of the knee, for lesions
measuring less than 4 cm2, these procedures give good early
results, but they deteriorate over time. Several authors
have reported their unfavorable effect in cases of sec-
ondary grafting, contrary to certain widely held beliefs.
More recently, subchondral bone stimulation procedures
have been associated with covering with a membrane or a
3D multilayer substitute, providing better ﬁlling and there-
fore better results. These PLUS microfractures provide good
short-term results, but require long-term assessment com-
pared to the much more expensive cell culture techniques.
Mosaicplasty is part of the reconstruction techniques, bring-
ing mature cartilage to the osteochondral unit. This is a
highly demanding technique that can be done with arthro-
scopic guidance for a maximum of two or three pegs, or
otherwise with arthrotomy. All authors agree to indicate
this procedure for lesions measuring at least 2 cm2, partic-
ularly for the condyles, providing 75—90% good and very
good results at medium and long terms, sometimes with
problems of hyaline cartilage integration. Autologous chon-
drocyte culture grafting has greatly progressed in the past
10 years, evolving from culture under a periosteum patch to
third-generation matrices, particularly for solving the prob-
lem of ﬁlling and immediate congruence. This technique is
indicated for lesions that are larger than 2 cm2. However,
two sizeable problems persist: cost (equivalent to at last
ﬁve TKA procedures) and particularly the need for in situ
alchemy, not yet sufﬁciently under control, but nonetheless
indispensable to maturation. Although the clinical results
are good and long-lasting, hyaline cartilage does not always
appear. This is where the importance of research in mul-
tilayer molecular surfaces and cell selection in cultures
becomes all important.
Finally, salvage procedures can turn to chondrocyte
culture, but particularly to autografting procedures, an easy
but expensive technique for the countries that have this
available. These allografts (Fig. 14) are reserved for cases of
substantial cartilage defect — greater than 4 cm2 — and give
good results, even though no prospective series has been
reported. Other than viral transmission, bone integration
remains a problem. The therapeutic choice should take sev-
eral factors into account: the type of lesion (OCD or chondral
fracture), location, size, depth, patient age, desired level of
activity, morphotype, and ﬁnally the armamentarium avail-
able.
Overall, for cases of osteochondritis (Fig. 15), we follow
the SoFCOT recommendations. When the joint cartilage is
closed (SoFCOT stage I), perforation in cases of question-
able vitality of the nodule on MRI will give greater certainty
and satisfaction compared to screw ﬁxation (Fig. 16). If
the cartilage is open (stage II), the lesion is unstable, and
the PLUS ﬁxation proposed by Bernard Moyen, will provide
a good success rate, associating revascularization through
freshening of the bed and possibly mixed ﬁxation as per-
formed by Beauﬁls (Fig. 17). When the bed is empty (stage
III), simple ablation of the free loose body (LB) outside the
nonloadbearing areas should be abandoned; this incongru-
ence (Fig. 18) will lead to early osteoarthritis. Filling should
be preferred, with the choice depending on the size of theigure 17 PLUS ﬁxation in a case of osteochondritis disse-
ans.
ed. Under 2 cm2, mosaicplasty gives reliable results, par-Figure 18 Empty osteochondritis cavity.
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SFA 2010 and Hangody series). Small lesions are treated with
a few mosaicplasty pegs, with mediocre results: 55—75%
good results [30,35]. If microfracturing is chosen here, the
results are comparable. Recent articles advocate nearlyFigure 19 Decision tree fo
For osteochondral fractures (Fig. 19), the decision will
epend on the size and the patient’s activity. Mosaicplasty
s a choice treatment for lesions less than 2 cm2, and in the
uture, depending on the results, PLUS microfracturing may
ccupy an important place. Larger lesions are the domain
f chondrocyte grafting. Finally, lesions greater than 4 cm2
ill be treated with either chondrocyte grafting or allo-
raft, or mega-OATS®, with results that have not undergone
s extensive scientiﬁc assessment, therefore making them
ess reliable. As for the choice according to the patient’s
ctivity level, the current trend is to propose regeneration
echniques to young and active patients and other repair or
econstruction techniques to less active patients.
Tibial lesions are rare. Small (less than 1 cm2) lesions
ccessible with the alignment guide Fig. 20) are treated
ith retrograde mosaicplasty, which according to Hang-
dy provides 87% good results. Larger tibial lesions are
referentially treated with microfracturing, matrix, or 3D
hondrocyte culture, but here also there has not yet been
ufﬁcient follow-up and numbers of patients for reliable
esults.
In 2010, trochlear-patellar lesions continue to have a
oor prognosis (respectively 55% and 79% ICRS A and B in the
Figure 20 Positioning the ligament reconstruction alignment
device in the middle of the tibial defect.
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systematic realignment of the extensor system at the same
time as chondrocyte grafting. Without being extremist, with
these infrequent lesions (8% of the SFA series) we propose
an à la carte menu depending on the usual lesions of this
pathology, modifying the alignment and/or the patellar
height in cases of objective instability.
Conclusions
Each osteochondral lesion of the knee is an entity in itself.
Surgical management will be proposed only if the patient
is symptomatic (ICRS C and D), if the lesion is deep (ICRS
stage III and IV), respecting the surgical contraindications, in
particular morbid obesity, axis defects, laxity, and especially
osteoarthritis, which is an absolute contraindication.
The preoperative workup should be well documented:
clinically according to the ICRS 2000 and morphologically on
MRI with ICRS sequences for the MOCART score, well known
to referent radiologists. Validated indications must be used
and one must remain cautious with the emerging techniques
that have not been fully validated. The established algo-
rithms are based on the literature results and also depend
on local accessibility of the different techniques.
In France, mosaicplasty is the reference technique that
can treat the majority of lesions. It is a delicate tech-
nique to learn. Chondrocyte grafting should be reserved for
lesions larger than 2 cm2. As for isolated microfracturing,
they retain their utility for patients who require a low level
of functioning.
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